A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: The AFR-15 trial - Chevallier, Patrice; Hunault-Berger, Mathilde; Larosa, Fabrice; Dauriac, Charles; Garand, Richard; Harousseau, Jean-Luc (Leukemia Research, 2009)